Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients

Clinical Nuclear Medicine

Volumn 42, Issue 1, 2017, Pages e29-e34

  Bluemel, Christina ^a   Hahner, Stefanie ^b   Heinze, Britta ^b   Fassnacht, Martin ^b,c   Kroiss, Matthias ^c   Bley, Thorsten A ^a   Wester, Hans Juergen ^d,e   Kropf, Saskia ^e   Lapa, Constantin ^a   Schirbel, Andreas ^a   Buck, Andreas K ^a   Herrmann, Ken ^f  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Division of Endocrinology   (United States)

^c Division of Human Genetics   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e SCINTOMICS GMBH   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adrenocortical cancer; chemokine receptor; CXCR4; in vivo imaging; PET CT

Indexed keywords

CHEMOKINE RECEPTOR CCR4; FLUORODEOXYGLUCOSE F 18; PENTIXAFOR GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 177LU-PENTIXATHER; 68GA-PENTIXAFOR; 90Y-PENTIXATHER; CHEMOKINE RECEPTOR CXCR4; COORDINATION COMPOUND; CXCR4 PROTEIN, HUMAN; CYCLOPEPTIDE; GALLIUM; LUTETIUM; PEPTIDE; RADIOISOTOPE; YTTRIUM;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISTANT METASTASIS; FEASIBILITY STUDY; FEMALE; HUMAN; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; MALE; PERITONEUM METASTASIS; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATIENT SELECTION; SCINTISCANNING;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; COORDINATION COMPLEXES; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; LUTETIUM; MALE; MIDDLE AGED; PATIENT SELECTION; PEPTIDES; PEPTIDES, CYCLIC; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RADIOISOTOPES; RADIONUCLIDE IMAGING; RADIOTHERAPY; RECEPTORS, CXCR4; YTTRIUM RADIOISOTOPES;

EID: 84994673193     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001435     Document Type: Article

References (32)

1. Kebebew E, Reiff E,DuhQY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872-878.
2. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579-2586.
3. Libe R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015;3:45.
4. Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282-326.
5. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992;112:963-970 discussion 970-971.
6. Stojadinovic A,Ghossein RA,Hoos A, et al.Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20: 941-950.
7. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-2380.
8. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189-2197.
9. Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii131-vii138.
10. Kreissl MC, Schirbel A, Fassnacht M, et al. [123I]iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98: 2755-2764.
11. Hahner S, Stuermer A, Kreissl M, et al. [123I]iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab. 2008;93:2358-2365.
12. Hahner S, Kreissl MC, Fassnacht M, et al. Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. J Clin EndocrinolMetab. 2013; 98:1508-1518.
13. Hahner S, KreisslMC, Fassnacht M, et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:914-922.
14. Liotta LA. An attractive force in metastasis. Nature. 2001;410:24-25.
15. CojocM, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Oncol Targets Ther. 2013;6: 1347-1361.
16. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43-52.
17. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/ CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49: 219-230.
18. Wester HJ, Keller U, Schottelius M, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5:618-630.
19. Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015;7:477-487.
20. Herrmann K, Lapa C, Wester HJ, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J NuclMed. 2015;56:410-416.
21. Herrmann K, Schottelius M, Lapa C, et al. First-in-man experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labelled pentixather in advanced stage multiple myeloma with extensive intra-and extramedullary disease. J Nucl Med. 2016;57:248-251.
22. Heinze B, Bluemel C, Chifu I, et al. A novel theranostic concept for adrenocortical neoplasia targeting the chemokine receptor CXCR4. Exp Clin Endocrinol Diabetes. 2015 123-OP121-101.
23. HaugAR, Cindea-Drimus R,Auernhammer CJ, et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology. 2014;270: 517-525.
24. Demmer O, Gourni E, Schumacher U, et al. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem. 2011;6:1789-1791.
25. Gourni E, Demmer O, Schottelius M, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52: 1803-1810.
26. Martin R, Juttler S, Muller M, et al. Cationic eluate pretreatment for automated synthesis of [68Ga]CPCR4.2. Nucl Med Biol. 2014;41:84-89.
27. Vag T, Gerngross C,Herhaus P, et al. First experiencewith chemokine receptor CXCR4-targeted PETimaging of patientswith solid cancers. JNuclMed. 2016;57:741-746.
28. Ardito A, Massaglia C, Pelosi E, et al. 18 F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. Eur J Endocrinol. 2015;173:749-756.
29. Takeuchi S, Balachandran A, Habra MA, et al. Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging. 2014;41:2066-2073.
30. Fuß C, Heinze B, Hirsch K, et al. High expression of C-X-C chemokine receptor 4 in the zona glomerulosa and in aldosterone procuding adenoma. Exp Clin Endocrinol Diabetes. 2015;123 P09-02.
31. Herrmann K, Schottelius M, Lapa C, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease. J Nucl Med. 2016;57:248-251.
32. WuW, Qian L, Chen X, et al. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer. Int J Clin Exp Pathol. 2015;8: 13217-13224.